A Phase 3, Randomized, Open-Label Study To Evaluate Safety And Efficacy Of Epcoritamab In Combination With R-Chop Compared To R-Chop In Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl)
Posted Date: Apr 25, 2024
- Investigator: Tahir Latif
- Specialties:
- Type of Study: Drug
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL).
Criteria:
Null
Keywords:
Lymphoma
For More Information:
Emily Greve
NULL
cancer@uchealth.com